Breaking News Instant updates and real-time market news.

ATRA

Atara Biotherapeutics

$11.22 /

+0.1 (+0.90%)

08:23
02/27/20
02/27
08:23
02/27/20
08:23

Atara Biotherapeutics remains on track to initiate tab-cel BLA in 2H20

Atara continues to progress tab-cel Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease. Atara remains on track to initiate a tab-cel biologics license application submission for patients with EBV+ PTLD in the second half of 2020. Atara plans to discuss the totality of tab-cel results with the U.S. Food and Drug Administration in a pre-BLA meeting prior to initiating the BLA submission. In the U.S. and Australia, 38 sites are available for enrollment and the Company is preparing to open additional sites in the U.S., Canada and Europe. Atara submitted clinical trial applications to several European countries in November and December 2019 to enable the opening of EU clinical sites in 2020. The Company's CTAs in the United Kingdom, Spain and Austria were recently approved. Atara recently submitted a Pediatric Investigation Plan to the European Medicines Agency. Following EMA approval of the PIP, Atara plans to submit a tab-cel EU marketing authorization application for patients with EBV+ PTLD in 2021. Atara continues to see strong tab-cel investigator, physician and patient interest and, for cases in which the Company is not able to enroll patients in its EBV+ PTLD Phase 3 clinical study, Atara is providing tab-cel to patients in need under its expanded access protocol and single patient use programs. In December 2019, Atara presented long-term clinical results for 61 patients with diverse EBV-associated diseases, including efficacy and safety data for 26 patients with relapsed/refractory EBV+ PTLD and safety findings for 35 patients with other EBV-associated diseases, from a multicenter EAP study of tab-cel at the 61st American Society of Hematology Annual Meeting & Exposition. Results from this analysis suggest a high overall response rate, short time to response and favorable estimated long-term overall survival rates for tab-cel in patients with EBV+ PTLD following hematopoietic cell transplant or solid organ transplant who have failed rituximab-based therapy. Tab-cel was shown to be generally well-tolerated in all patients with EBV+ PTLD and other EBV-associated diseases. Studies supporting potential additional tab-cel indications are also advancing . Atara expects to initiate enrollment in a tab-cel Phase 2 multi-cohort study including up to six additional ultra-rare EBV+ diseases in the second half of 2020 based on previous clinical data treating these patients. Atara enrolled the final planned patient in the Phase 1b portion of a Phase 1b/2 clinical study of tab-cel(R) in combination with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with platinum-resistant or recurrent EBV-associated nasopharyngeal carcinoma.

  • 27

    Feb

  • 02

    Mar

  • 10

    Mar

ATRA Atara Biotherapeutics
$11.22 /

+0.1 (+0.90%)

11/08/19 JPMorgan
Atara Biotherapeutics downgraded to on lack of catalysts at JPMorgan
11/08/19 JPMorgan
Atara Biotherapeutics downgraded to Neutral from Overweight at JPMorgan
10/25/19 Stifel
Stifel recommend buying into weakness on Atara Biotherapeutics CSO resignation
10/25/19 Mizuho
Mizuho says CSO Chris Haqq to remain on as Atara adviser

TODAY'S FREE FLY STORIES

Periodicals
Production ramp-up for 5G iPhones at Apple suppliers postponed, Reuters reports » 05:58
03/30/20
03/30
05:58
03/30/20
05:58
AAPL

Apple

$247.74 /

-10.74 (-4.16%)

The production ramp-up…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Venator Materials downgraded to Neutral from Buy at Goldman Sachs » 05:55
03/30/20
03/30
05:55
03/30/20
05:55
VNTR

Venator Materials

$1.85 /

-0.22 (-10.63%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Livent downgraded to Neutral from Buy at Goldman Sachs » 05:52
03/30/20
03/30
05:52
03/30/20
05:52
LTHM

Livent

$5.30 /

-0.52 (-8.94%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Univar upgraded to Buy from Neutral at Goldman Sachs » 05:51
03/30/20
03/30
05:51
03/30/20
05:51
UNVR

Univar

$10.49 /

-1.04 (-9.02%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
GFL Environmental initiated with a Neutral at CIBC » 05:50
03/30/20
03/30
05:50
03/30/20
05:50
GFL

GFL Environmental

$14.95 /

-0.09 (-0.60%)

CIBC analyst Kevin Chiang…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
GFL Environmental initiated with an Outperform at Scotiabank » 05:49
03/30/20
03/30
05:49
03/30/20
05:49
GFL

GFL Environmental

$14.95 /

-0.09 (-0.60%)

Scotiabank initiated…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Eastman Chemical downgraded to Neutral from Buy at Goldman Sachs » 05:49
03/30/20
03/30
05:49
03/30/20
05:49
EMN

Eastman Chemical

$46.38 /

-1.75 (-3.64%)

, CE

Celanese

$71.26 /

-4.26 (-5.64%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
ASML updates market on expected Q1 results, primarily related to COVID-19 impact » 05:48
03/30/20
03/30
05:48
03/30/20
05:48
ASML

ASML

$252.25 /

-24.66 (-8.91%)

ASML Holding provides an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Celanese upgraded to Buy from Neutral at Goldman Sachs » 05:47
03/30/20
03/30
05:47
03/30/20
05:47
CE

Celanese

$71.26 /

-4.26 (-5.64%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Linde plc upgraded to Buy from Neutral at Goldman Sachs » 05:44
03/30/20
03/30
05:44
03/30/20
05:44
LIN

Linde plc

$167.18 /

-7.06 (-4.05%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Sherwin-Williams upgraded to Conviction Buy from Neutral at Goldman Sachs » 05:41
03/30/20
03/30
05:41
03/30/20
05:41
SHW

Sherwin-Williams

$461.17 /

-3.92 (-0.84%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Republic Services upgraded to Overweight from Neutral at JPMorgan » 05:38
03/30/20
03/30
05:38
03/30/20
05:38
RSG

Republic Services

$75.45 /

-2.14 (-2.76%)

JPMorgan analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
ING Group suspends dividend payment due to COVID-19 » 05:35
03/30/20
03/30
05:35
03/30/20
05:35
ING

ING Group

$6.04 /

-0.44 (-6.79%)

ING provided the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Mondelez upgraded to Buy from Hold at Stifel » 05:35
03/30/20
03/30
05:35
03/30/20
05:35
MDLZ

Mondelez

$47.61 /

-0.93 (-1.92%)

Stifel analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Regeneron, Sanofi announce first patient outside U.S. treated in Kevzara study » 05:33
03/30/20
03/30
05:33
03/30/20
05:33
REGN

Regeneron

$448.05 /

-4.26 (-0.94%)

, SNY

Sanofi

$42.47 /

-0.48 (-1.12%)

Regeneron Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
GFL Environmental initiated with a Buy at Stifel » 05:31
03/30/20
03/30
05:31
03/30/20
05:31
GFL

GFL Environmental

$14.95 /

-0.09 (-0.60%)

Stifel analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Carbo Ceramics to be acquired by Wilks Brothers » 05:30
03/30/20
03/30
05:30
03/30/20
05:30
CRR

Carbo Ceramics

$0.00 /

+ (+0.00%)

CARBO Ceramics announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Upgrade
Magellan Midstream upgraded to Buy from Underperform at BofA » 05:29
03/30/20
03/30
05:29
03/30/20
05:29
MMP

Magellan Midstream

$33.53 /

-0.92 (-2.67%)

BofA analyst Derek Walker…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
International Paper agrees to sell Brazilian corrugated packaging business » 05:28
03/30/20
03/30
05:28
03/30/20
05:28
IP

International Paper

$30.60 /

-0.45 (-1.45%)

International Paper has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Moderna provides update on COVID-19 impact » 05:27
03/30/20
03/30
05:27
03/30/20
05:27
MRNA

Moderna

$30.01 /

+2.1 (+7.52%)

Moderna provided an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Polaris Industries downgraded to Market Perform from Outperform at BMO Capital » 05:26
03/30/20
03/30
05:26
03/30/20
05:26
PII

Polaris Industries

$47.25 /

-5.545 (-10.50%)

BMO Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
NeoPhotonics upgraded to Overweight from Neutral at Piper Sandler » 05:23
03/30/20
03/30
05:23
03/30/20
05:23
NPTN

NeoPhotonics

$6.72 /

-0.045 (-0.67%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
AstraZeneca says FARXIGA reduced incidence of heart failure worsening » 05:23
03/30/20
03/30
05:23
03/30/20
05:23
AZN

AstraZeneca

$42.56 /

+0.26 (+0.61%)

New data from a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Cleveland-Cliffs reinstated with a Neutral at Goldman Sachs » 05:20
03/30/20
03/30
05:20
03/30/20
05:20
CLF

Cleveland-Cliffs

$3.79 /

-0.1 (-2.57%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Stelco Holdings downgraded to Sell from Neutral at Goldman Sachs » 05:18
03/30/20
03/30
05:18
03/30/20
05:18
STZHF

Stelco Holdings

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.